Target Price | CHF19.38 |
Price | CHF10.90 |
Potential |
77.80%
register free of charge
|
Number of Estimates | 4 |
4 Analysts have issued a price target Medmix 2026 .
The average Medmix target price is CHF19.38.
This is
77.80%
register free of charge
CHF21.00
92.66%
register free of charge
CHF18.18
66.79%
register free of charge
|
|
A rating was issued by 8 analysts: 7 Analysts recommend Medmix to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Medmix stock has an average upside potential 2026 of
77.80%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million CHF | 483.90 | 490.22 |
0.55% | 1.31% | |
EBITDA Margin | 16.62% | 17.64% |
10.15% | 6.17% |
4 Analysts have issued a sales forecast Medmix 2025 . The average Medmix sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Medmix EBITDA forecast 2025. The average Medmix EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share CHF | -0.18 | 0.34 |
1,900.00% | 288.89% | |
P/E | 32.26 | |
EV/Sales | 1.35 |
4 Analysts have issued a Medmix forecast for earnings per share. The average Medmix EPS is
This results in the following potential growth metrics and future valuations:
Analyst | Rating | Action | Date |
---|---|---|---|
RESEARCH PARTNERS AG |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
Analyst Rating | Date |
---|---|
Locked
RESEARCH PARTNERS AG:
Locked
➜
Locked
|
Feb 26 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.